Close Menu

NEW YORK ─ ArcherDx announced on Thursday a collaboration with New York-based biopharmaceutical firm Bristol Myers Squibb to use the genomic analysis company's personalized cancer monitoring (PCM) assays for minimal residual disease (MRD) detection in cancer patients treated with immunotherapy.

ArcherDx said the firms will evaluate clinical samples from cancer-patient cohorts to advance MRD detection or ctDNA clearance to potentially inform future therapy selection or optimization, or both.

Financial and other terms of the collaboration were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.